Shenzhen Exchange seeks clarity on swine fever vaccine
Highsun backs research into natural compound but may not have official approval
13 June 2019 - 19:11
Beijing — China’s Shenzhen Stock Exchange said on Thursday it is seeking further information from shopping mall operator Guangdong Highsun Group after Highsun announced it was backing the development of an African swine fever vaccine.
Highsun said on Tuesday that it would spend 900-million yuan ($130.09m), or 26% of its 2018 net assets, on supporting research into a natural compound the company claimed had been shown to prevent African swine fever, a disease deadly to pigs that is ravaging herds across Asia...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.